Ionis Pharmaceuticals (IONS) – Research Analysts’ Weekly Ratings Changes

by · The Cerbat Gem

Several analysts have recently updated their ratings and price targets for Ionis Pharmaceuticals (NASDAQ: IONS):

  • 6/25/2026 – Ionis Pharmaceuticals had its price target raised by HC Wainwright from $125.00 to $130.00. They now have a “buy” rating on the stock.
  • 6/25/2026 – Ionis Pharmaceuticals had its price target raised by Leerink Partners from $122.00 to $129.00. They now have an “outperform” rating on the stock.
  • 6/24/2026 – Ionis Pharmaceuticals had its price target raised by The Goldman Sachs Group, Inc. from $74.00 to $75.00. They now have a “neutral” rating on the stock.
  • 6/17/2026 – Ionis Pharmaceuticals had its price target raised by Leerink Partners from $114.00 to $122.00. They now have an “outperform” rating on the stock.
  • 6/15/2026 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by TD Cowen. They now have a $108.00 price target on the stock.
  • 5/27/2026 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $125.00 price target on the stock.
  • 5/18/2026 – Ionis Pharmaceuticals is now covered by Citigroup Inc.. They set a “buy” rating and a $115.00 price target on the stock.
  • 5/18/2026 – Ionis Pharmaceuticals was upgraded by Citigroup Inc. from “buy” to “strong-buy”.
  • 5/2/2026 – Ionis Pharmaceuticals was upgraded by Wall Street Zen from “strong sell” to “hold”.
  • 4/30/2026 – Ionis Pharmaceuticals had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $111.00 price target on the stock.
  • 4/30/2026 – Ionis Pharmaceuticals had its price target raised by HC Wainwright from $120.00 to $125.00. They now have a “buy” rating on the stock.
  • 4/30/2026 – Ionis Pharmaceuticals had its price target raised by Barclays PLC from $106.00 to $115.00. They now have an “overweight” rating on the stock.
  • 4/30/2026 – Ionis Pharmaceuticals had its price target raised by Royal Bank Of Canada from $95.00 to $100.00. They now have an “outperform” rating on the stock.

Insider Buying and Selling

In other news, Director Spencer R. Berthelsen sold 8,000 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $73.49, for a total transaction of $587,920.00. Following the sale, the director owned 156,013 shares in the company, valued at approximately $11,465,395.37. The trade was a 4.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Brian Birchler sold 973 shares of the company’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $75.04, for a total transaction of $73,013.92. Following the completion of the sale, the executive vice president directly owned 67,500 shares in the company, valued at $5,065,200. This represents a 1.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 190,153 shares of company stock valued at $14,606,373 over the last 90 days. 1.81% of the stock is currently owned by company insiders.

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.

See Also